PHARMING GRP SP. ADRS (PHG) — Tangible Net Worth Ratio
PHARMING GRP SP. ADRS (PHG) has a Tangible Net Worth Ratio of 52.3% as of December 2025. This metric is calculated by deducting intangible assets (€132.22 Million) from net assets (€277.10 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See PHG net assets for net asset value and shareholders' equity analysis.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
PHARMING GRP SP. ADRS Tangible Net Worth Ratio (2021–2025)
This chart shows how PHARMING GRP SP. ADRS's Tangible Net Worth Ratio has changed across 5 annual periods from 2021 to 2025. As of December 2025, the ratio stands at 52.3%, reflecting net assets of €277.10 Million with intangible assets of €132.22 Million EUR. Also explore PHARMING GRP SP. ADRS (PHG) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for PHARMING GRP SP. ADRS (2021–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for PHARMING GRP SP. ADRS from 2021 to 2025, covering 5 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see PHARMING GRP SP. ADRS (PHG) market capitalisation.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 52.3% | €277.10 Million | €132.22 Million | €499.96 Million | ▼ -20.1 pp |
| 2024 | 72.4% | €221.06 Million | €61.04 Million | €399.99 Million | ▲ +5.0 pp |
| 2023 | 67.4% | €218.78 Million | €71.27 Million | €462.85 Million | ▲ +4.1 pp |
| 2022 | 63.3% | €204.64 Million | €75.12 Million | €425.80 Million | ▲ +6.7 pp |
| 2021 | 56.5% | €192.92 Million | €83.83 Million | €397.31 Million | — |